chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 63.0
Sex: F
Vaccine: RSV, RSV, RSV
Symptoms: Arthralgia, Headache, Injection site discolouration, Injection site infection, Injection site reaction
Clinical narrative: PATIENT CAME TO PHARMACY ABOUT 10 DAYS LATER WITH QUESTIONS ABOUT WHETHER HER ARM SHOULD STILL BE HURTING. SHE SAID IT HAD GOTTEN BETTER IN THE 2 DAYS AFTER THE VACCINE BUT HAD GOTTEN WORSE AND THE PAIN WAS EXTENDING DOWN HER WHOLE ARM. HER DR OFFICE WAS CLOSED AND I ADVISED SHE SHOULD BE BETTER BY NOW BUT THAT IF IT WAS NOT BETTER BY MONDAY SHE SHOULD CONSULT HER PCP. THE NEXT WEEK, SHE RECIEVED ANTIBIOTICS FROM HER PCP. ABOUT 10 DAYS AFTER THAT SHE CAME BACK TO THE PHARMACY AND WANTED ME TO LOOK AT THE SITE AGAIN.  AT THIS POINT I OBSERVED A DARK BLACK SPOT AT THE ORIGINAL INJECTION SITE. I ADVISED THIS WAS NOT NORMAL AND SHE SHOULD CONTACT HER PCP FOR FURTHER EVAL. SHE WENT TO THE DR THE NEXT DAY AND THE DR ADVISED THAT THE INFECTION WAS FLESH EATING AND INTO THE MUSCLE AND  SHE WOULD NEED SURGERY TO REMOVE. SHE THEN FOLLOWED UP WITH A DERMATOLOGIST ABOUT 4 DAYS LATER AND HE RECOMMENDED THE SAME. HE WILL PERFORM THIS PROCEDURE IN A WEEK. SHE REPORTS OVERALL FELLING OF MALAISE AND HEADACHE THAT WILL NOT GO AWAY. PAIN STILL IN ARM THAT RADIATES TO SHOULDER.
Age: 63.0
Sex: F
Vaccine: RSV, RSV, RSV
Symptoms: Malaise, Necrotising fasciitis, Pain, Pain in extremity
Clinical narrative: PATIENT CAME TO PHARMACY ABOUT 10 DAYS LATER WITH QUESTIONS ABOUT WHETHER HER ARM SHOULD STILL BE HURTING. SHE SAID IT HAD GOTTEN BETTER IN THE 2 DAYS AFTER THE VACCINE BUT HAD GOTTEN WORSE AND THE PAIN WAS EXTENDING DOWN HER WHOLE ARM. HER DR OFFICE WAS CLOSED AND I ADVISED SHE SHOULD BE BETTER BY NOW BUT THAT IF IT WAS NOT BETTER BY MONDAY SHE SHOULD CONSULT HER PCP. THE NEXT WEEK, SHE RECIEVED ANTIBIOTICS FROM HER PCP. ABOUT 10 DAYS AFTER THAT SHE CAME BACK TO THE PHARMACY AND WANTED ME TO LOOK AT THE SITE AGAIN.  AT THIS POINT I OBSERVED A DARK BLACK SPOT AT THE ORIGINAL INJECTION SITE. I ADVISED THIS WAS NOT NORMAL AND SHE SHOULD CONTACT HER PCP FOR FURTHER EVAL. SHE WENT TO THE DR THE NEXT DAY AND THE DR ADVISED THAT THE INFECTION WAS FLESH EATING AND INTO THE MUSCLE AND  SHE WOULD NEED SURGERY TO REMOVE. SHE THEN FOLLOWED UP WITH A DERMATOLOGIST ABOUT 4 DAYS LATER AND HE RECOMMENDED THE SAME. HE WILL PERFORM THIS PROCEDURE IN A WEEK. SHE REPORTS OVERALL FELLING OF MALAISE AND HEADACHE THAT WILL NOT GO AWAY. PAIN STILL IN ARM THAT RADIATES TO SHOULDER.
Age: 63.0
Sex: F
Vaccine: RSV, RSV, RSV
Symptoms: Injection site bruising, Neck pain, Nodule, Pain, Pain in extremity
Clinical narrative: PATIENT CAME TO PHARMACY ABOUT 10 DAYS LATER WITH QUESTIONS ABOUT WHETHER HER ARM SHOULD STILL BE HURTING. SHE SAID IT HAD GOTTEN BETTER IN THE 2 DAYS AFTER THE VACCINE BUT HAD GOTTEN WORSE AND THE PAIN WAS EXTENDING DOWN HER WHOLE ARM. HER DR OFFICE WAS CLOSED AND I ADVISED SHE SHOULD BE BETTER BY NOW BUT THAT IF IT WAS NOT BETTER BY MONDAY SHE SHOULD CONSULT HER PCP. THE NEXT WEEK, SHE RECIEVED ANTIBIOTICS FROM HER PCP. ABOUT 10 DAYS AFTER THAT SHE CAME BACK TO THE PHARMACY AND WANTED ME TO LOOK AT THE SITE AGAIN.  AT THIS POINT I OBSERVED A DARK BLACK SPOT AT THE ORIGINAL INJECTION SITE. I ADVISED THIS WAS NOT NORMAL AND SHE SHOULD CONTACT HER PCP FOR FURTHER EVAL. SHE WENT TO THE DR THE NEXT DAY AND THE DR ADVISED THAT THE INFECTION WAS FLESH EATING AND INTO THE MUSCLE AND  SHE WOULD NEED SURGERY TO REMOVE. SHE THEN FOLLOWED UP WITH A DERMATOLOGIST ABOUT 4 DAYS LATER AND HE RECOMMENDED THE SAME. HE WILL PERFORM THIS PROCEDURE IN A WEEK. SHE REPORTS OVERALL FELLING OF MALAISE AND HEADACHE THAT WILL NOT GO AWAY. PAIN STILL IN ARM THAT RADIATES TO SHOULDER.
Age: 63.0
Sex: F
Vaccine: RSV, RSV, RSV
Symptoms: Skin discolouration, Tenderness
Clinical narrative: PATIENT CAME TO PHARMACY ABOUT 10 DAYS LATER WITH QUESTIONS ABOUT WHETHER HER ARM SHOULD STILL BE HURTING. SHE SAID IT HAD GOTTEN BETTER IN THE 2 DAYS AFTER THE VACCINE BUT HAD GOTTEN WORSE AND THE PAIN WAS EXTENDING DOWN HER WHOLE ARM. HER DR OFFICE WAS CLOSED AND I ADVISED SHE SHOULD BE BETTER BY NOW BUT THAT IF IT WAS NOT BETTER BY MONDAY SHE SHOULD CONSULT HER PCP. THE NEXT WEEK, SHE RECIEVED ANTIBIOTICS FROM HER PCP. ABOUT 10 DAYS AFTER THAT SHE CAME BACK TO THE PHARMACY AND WANTED ME TO LOOK AT THE SITE AGAIN.  AT THIS POINT I OBSERVED A DARK BLACK SPOT AT THE ORIGINAL INJECTION SITE. I ADVISED THIS WAS NOT NORMAL AND SHE SHOULD CONTACT HER PCP FOR FURTHER EVAL. SHE WENT TO THE DR THE NEXT DAY AND THE DR ADVISED THAT THE INFECTION WAS FLESH EATING AND INTO THE MUSCLE AND  SHE WOULD NEED SURGERY TO REMOVE. SHE THEN FOLLOWED UP WITH A DERMATOLOGIST ABOUT 4 DAYS LATER AND HE RECOMMENDED THE SAME. HE WILL PERFORM THIS PROCEDURE IN A WEEK. SHE REPORTS OVERALL FELLING OF MALAISE AND HEADACHE THAT WILL NOT GO AWAY. PAIN STILL IN ARM THAT RADIATES TO SHOULDER.
Age: 63.0
Sex: F
Vaccine: RSV, RSV, RSV
Symptoms: Bacterial infection, Headache, Injection site infection, Malaise, Pain
Clinical narrative: PATIENT CAME TO PHARMACY ABOUT 10 DAYS LATER WITH QUESTIONS ABOUT WHETHER HER ARM SHOULD STILL BE HURTING. SHE SAID IT HAD GOTTEN BETTER IN THE 2 DAYS AFTER THE VACCINE BUT HAD GOTTEN WORSE AND THE PAIN WAS EXTENDING DOWN HER WHOLE ARM. HER DR OFFICE WAS CLOSED AND I ADVISED SHE SHOULD BE BETTER BY NOW BUT THAT IF IT WAS NOT BETTER BY MONDAY SHE SHOULD CONSULT HER PCP. THE NEXT WEEK, SHE RECIEVED ANTIBIOTICS FROM HER PCP. ABOUT 10 DAYS AFTER THAT SHE CAME BACK TO THE PHARMACY AND WANTED ME TO LOOK AT THE SITE AGAIN.  AT THIS POINT I OBSERVED A DARK BLACK SPOT AT THE ORIGINAL INJECTION SITE. I ADVISED THIS WAS NOT NORMAL AND SHE SHOULD CONTACT HER PCP FOR FURTHER EVAL. SHE WENT TO THE DR THE NEXT DAY AND THE DR ADVISED THAT THE INFECTION WAS FLESH EATING AND INTO THE MUSCLE AND  SHE WOULD NEED SURGERY TO REMOVE. SHE THEN FOLLOWED UP WITH A DERMATOLOGIST ABOUT 4 DAYS LATER AND HE RECOMMENDED THE SAME. HE WILL PERFORM THIS PROCEDURE IN A WEEK. SHE REPORTS OVERALL FELLING OF MALAISE AND HEADACHE THAT WILL NOT GO AWAY. PAIN STILL IN ARM THAT RADIATES TO SHOULDER.
Age: 63.0
Sex: F
Vaccine: RSV, RSV, RSV
Symptoms: Pain in extremity, Product complaint, Skin discolouration, Wound
Clinical narrative: PATIENT CAME TO PHARMACY ABOUT 10 DAYS LATER WITH QUESTIONS ABOUT WHETHER HER ARM SHOULD STILL BE HURTING. SHE SAID IT HAD GOTTEN BETTER IN THE 2 DAYS AFTER THE VACCINE BUT HAD GOTTEN WORSE AND THE PAIN WAS EXTENDING DOWN HER WHOLE ARM. HER DR OFFICE WAS CLOSED AND I ADVISED SHE SHOULD BE BETTER BY NOW BUT THAT IF IT WAS NOT BETTER BY MONDAY SHE SHOULD CONSULT HER PCP. THE NEXT WEEK, SHE RECIEVED ANTIBIOTICS FROM HER PCP. ABOUT 10 DAYS AFTER THAT SHE CAME BACK TO THE PHARMACY AND WANTED ME TO LOOK AT THE SITE AGAIN.  AT THIS POINT I OBSERVED A DARK BLACK SPOT AT THE ORIGINAL INJECTION SITE. I ADVISED THIS WAS NOT NORMAL AND SHE SHOULD CONTACT HER PCP FOR FURTHER EVAL. SHE WENT TO THE DR THE NEXT DAY AND THE DR ADVISED THAT THE INFECTION WAS FLESH EATING AND INTO THE MUSCLE AND  SHE WOULD NEED SURGERY TO REMOVE. SHE THEN FOLLOWED UP WITH A DERMATOLOGIST ABOUT 4 DAYS LATER AND HE RECOMMENDED THE SAME. HE WILL PERFORM THIS PROCEDURE IN A WEEK. SHE REPORTS OVERALL FELLING OF MALAISE AND HEADACHE THAT WILL NOT GO AWAY. PAIN STILL IN ARM THAT RADIATES TO SHOULDER.
Age: 39.0
Sex: M
Vaccine: HEP
Symptoms: Extra dose administered
Clinical narrative: I mistakenly gave a 3rd Heplisav injection one month later that 2 nd injection.
Age: 4.0
Sex: F
Vaccine: DTAPIPV, FLU4, HEPA, MMRV
Symptoms: No adverse event, Wrong product administered
Clinical narrative: No Adverse event.  Kinrix was given instead of giving separate Dtap and Polio vaccines.  Child did need 5th dose of Dtap and final dose of polio after age 4.  Child had already received 6 doses of Polio by age 2.  Kinrix was given outside of licensure recommendations. Dtap and Polio should have been given as separate vaccinations instead of the combination. Follow up with parent who denied any adverse events and will continue to watch for them.
Age: 2.0
Sex: M
Vaccine: COVID19
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: There was no reported adverse event from the patient. It was determined through a chart audit that the patient was given the wrong vaccine for their age range.  Patient was given Comirnaty 12+ when they should have received Pfizer Sars-Cov-2 Vaccination Pedi 6m-4y (2023-2024).
Age: 69.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Arthritis, Chondrocalcinosis, Condition aggravated, Inflammation
Clinical narrative: Multi-System Inflammation Joint pain, Stiffness - Both Hands - Inflammatory Arthritis Joint pain, Both Knees, Both Hips, Both Shoulders  Treatment - Prednisone, Methotrexate,   TIme Course - 10/31/23 to present
Age: 69.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Musculoskeletal stiffness, Osteoarthritis, X-ray limb abnormal
Clinical narrative: Multi-System Inflammation Joint pain, Stiffness - Both Hands - Inflammatory Arthritis Joint pain, Both Knees, Both Hips, Both Shoulders  Treatment - Prednisone, Methotrexate,   TIme Course - 10/31/23 to present
Age: 60.0
Sex: F
Vaccine: RSV
Symptoms: Immediate post-injection reaction, Injected limb mobility decreased, Injection site pain, Pain in extremity, Periarthritis
Clinical narrative: The RSV vaccine was given very high up in left arm and hurt terribly while being administered.  Within 5 hours my left arm was paralyzed with pain and it remained that way for several days.  Ever since the vaccine (almost 3 months) I have been in chronic pain in my left arm and I have been diagnosed with frozen shoulder as a result of SIRVA
Age: 60.0
Sex: F
Vaccine: RSV
Symptoms: Product administered at inappropriate site, Shoulder injury related to vaccine administration, X-ray limb normal
Clinical narrative: The RSV vaccine was given very high up in left arm and hurt terribly while being administered.  Within 5 hours my left arm was paralyzed with pain and it remained that way for several days.  Ever since the vaccine (almost 3 months) I have been in chronic pain in my left arm and I have been diagnosed with frozen shoulder as a result of SIRVA
Age: 27.0
Sex: M
Vaccine: HEP
Symptoms: Extra dose administered
Clinical narrative: I mistakenly gave a 3rd Heplisav injection one month later that 2 nd injection.
Age: 13.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product administered to patient of inappropriate age
Clinical narrative: There was no reported adverse event by the patient. It was discovered through a chart audit that the patient received the wrong covid vaccine for their age range. Patient received Pfizer(5-11 yrs.) and patient was 13 years old at the time the vaccine was given.
Age: 78.0
Sex: M
Vaccine: COVID19-2, HEP
Symptoms: Axillary pain, Oedema peripheral
Clinical narrative: Received Hep B and Pfizer Covid on the same day.  Requested both injections administered in right deltoid as his left arm has a dialysis port.  Later that evening he began to have pain and swelling in the right axilla.  Seen by provider today, referred to the ER for evaluation.
Age: 4.0
Sex: M
Vaccine: DTAPIPVHIB
Symptoms: Extra dose administered, No adverse event
Clinical narrative: No symptoms. Patient was administered Pentacel (DTaP + IPV + Hib) instead of DTaP + IPV. Mother informed. No questions. Will call if any concerns.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Head injury, Syncope
Clinical narrative: Patient fainted several minutes after receiving immunization hitting her head
Age: 80.0
Sex: F
Vaccine: PNC20
Symptoms: Blister, Erythema, Injection site erythema, Injection site reaction, Injection site vesicles
Clinical narrative: Patient was in for a well visit on 1/11/24 and received her Prevnar 20 vaccination at that visit.   She started with a rash on 1/19 that was red and itchy. It is worsening and spreading to her back/chest and face. Very itchy and tried Benadryl cream that didn't help. She has latex allergy and wonders if this was one of the preservatives in the shot. No difficulty breathing or swallowing. Intolerant to steroids including Prednisone and topicals mostly.  Was seen and evaluated on 1/21/24.  Provider notes: Appears healthy. No signs of acute distress present.  There is diffuse erythema of the left upper arm with overlying vesicles, some coalescing into bullae with a clear/yellow fluid inside. Maculopapular erythema. Instructed to Double dose of Claritin- 1 in AM and 1 in PM; Add Famotidine 20mg BID; apply Cool compresses and continue topical Benadryl cream.  On1/22/24 the patient continies to c/o itching  and left side of body is red and bumps some are ozining. Meds that she ordered yesterday have not done much yet. Still spreading.    Provider dded betamethasone topical cream use twice a day to affected areas.  Called patient on 2/6/24 and she states her symtoms have improved.   She was using goat soap and warm showers and appling Eucrin cream which helped.  Both itching and reddness improved.
Age: 80.0
Sex: F
Vaccine: PNC20
Symptoms: Pruritus, Rash, Rash erythematous, Rash maculo-papular, Rash pruritic
Clinical narrative: Patient was in for a well visit on 1/11/24 and received her Prevnar 20 vaccination at that visit.   She started with a rash on 1/19 that was red and itchy. It is worsening and spreading to her back/chest and face. Very itchy and tried Benadryl cream that didn't help. She has latex allergy and wonders if this was one of the preservatives in the shot. No difficulty breathing or swallowing. Intolerant to steroids including Prednisone and topicals mostly.  Was seen and evaluated on 1/21/24.  Provider notes: Appears healthy. No signs of acute distress present.  There is diffuse erythema of the left upper arm with overlying vesicles, some coalescing into bullae with a clear/yellow fluid inside. Maculopapular erythema. Instructed to Double dose of Claritin- 1 in AM and 1 in PM; Add Famotidine 20mg BID; apply Cool compresses and continue topical Benadryl cream.  On1/22/24 the patient continies to c/o itching  and left side of body is red and bumps some are ozining. Meds that she ordered yesterday have not done much yet. Still spreading.    Provider dded betamethasone topical cream use twice a day to affected areas.  Called patient on 2/6/24 and she states her symtoms have improved.   She was using goat soap and warm showers and appling Eucrin cream which helped.  Both itching and reddness improved.
Age: 80.0
Sex: F
Vaccine: PNC20
Symptoms: Skin weeping
Clinical narrative: Patient was in for a well visit on 1/11/24 and received her Prevnar 20 vaccination at that visit.   She started with a rash on 1/19 that was red and itchy. It is worsening and spreading to her back/chest and face. Very itchy and tried Benadryl cream that didn't help. She has latex allergy and wonders if this was one of the preservatives in the shot. No difficulty breathing or swallowing. Intolerant to steroids including Prednisone and topicals mostly.  Was seen and evaluated on 1/21/24.  Provider notes: Appears healthy. No signs of acute distress present.  There is diffuse erythema of the left upper arm with overlying vesicles, some coalescing into bullae with a clear/yellow fluid inside. Maculopapular erythema. Instructed to Double dose of Claritin- 1 in AM and 1 in PM; Add Famotidine 20mg BID; apply Cool compresses and continue topical Benadryl cream.  On1/22/24 the patient continies to c/o itching  and left side of body is red and bumps some are ozining. Meds that she ordered yesterday have not done much yet. Still spreading.    Provider dded betamethasone topical cream use twice a day to affected areas.  Called patient on 2/6/24 and she states her symtoms have improved.   She was using goat soap and warm showers and appling Eucrin cream which helped.  Both itching and reddness improved.
Age: 0.17
Sex: F
Vaccine: DTAPIPVHIB
Symptoms: No adverse event, Product preparation issue
Clinical narrative: This RN administered the diluent versus the full combining medication. Not constituted correctly, therefore vaccination not completely administered. This RN spoke with MOC and will be requesting full vaccination be given at next scheduled appt. No harm to pt.
Age: 33.0
Sex: F
Vaccine: COVID19-2, TDAP
Symptoms: Adverse reaction, Underdose
Clinical narrative: Pfizer 5-11 years vaccine was given in error to 33 year old patient. Patient did not exhibit any symptoms of adverse reaction.
Age: 55.0
Sex: M
Vaccine: HEP
Symptoms: Extra dose administered
Clinical narrative: I mistakenly gave a 3rd Heplisav injection one month later that 2 nd injection.
Age: 69.0
Sex: M
Vaccine: COVID19-2
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: Contracted Covid on 2-3-2024.  Started paxlovid on 2-6-2024.
Age: 76.0
Sex: M
Vaccine: RSV
Symptoms: Asthenia, Blood pressure increased, Fatigue, Heart rate increased
Clinical narrative: 12 HOURS AFTER VACCINATION, PATIENT EXPERIENCED INCREASED BLOOD PRESSURE (INCREASED 50 MMHG SYSTOLIC), INCREASED  HEART RATE (INCREASED 30 BBP), AND FELT WEAK AND  TIRED.
Age: 59.0
Sex: M
Vaccine: COVID19
Symptoms: Immediate post-injection reaction, Myalgia, Polymyalgia rheumatica
Clinical narrative: Adverse Effect: PMR (Polymyalgia Rheumatica) immediately after 2nd shot. Sever pain in many muscle groups.   Treatment: Prednizone and Methotrexate on and off for 2 years.  Outcome: Most pain eventually dissipated.
Age: 1.5
Sex: M
Vaccine: DTAP, HIBV
Symptoms: Erythema, Injection site erythema, Urticaria
Clinical narrative: *  immunization 1/23 with dtap and hib on thigh c/o large welt with redness/+/- heat          no fever / lesion is asymptomatic. EXTREMITIES/BACK: large erythematous  well  demarcated macule on left  anterior thigh measuring 2-3 inches - .
Age: 29.0
Sex: M
Vaccine: HEP
Symptoms: Extra dose administered
Clinical narrative: I mistakenly gave a 3rd Heplisav injection one month later that 2 nd injection.
Age: 18.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Given after 10 week beyond use date
Age: 60.0
Sex: M
Vaccine: HEP
Symptoms: Extra dose administered
Clinical narrative: I mistakenly gave a 3rd Heplisav injection one month later that 2 nd injection.
Age: 18.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Given after the beyond use date
Age: 18.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Given after the beyond use date.
Age: 24.0
Sex: M
Vaccine: HEP
Symptoms: Extra dose administered
Clinical narrative: Was given an extra dose (3) of Heplisav on 1/29/2024 one month after 2nd dose
Age: 77.0
Sex: F
Vaccine: FLU4, PNC20, VARZOS
Symptoms: Pain in extremity
Clinical narrative: Right arm pain, starting the day after administration and continuing until now. Patient has seen her primary care md and chiropractor for the pain.
Age: 26.0
Sex: F
Vaccine: TDAP
Symptoms: Foetal non-stress test, Maternal exposure before pregnancy, Rash, Syncope
Clinical narrative: G 5 P 0 0 4 0, 28.5, 04-25-2024 (GA as of today 2.6.24). Pt had an onset of syncope after standing up from the tdap vaccine from sitting position, and a rash on neck.
Age: 58.0
Sex: M
Vaccine: HEP
Symptoms: Inappropriate schedule of product administration
Clinical narrative: Mistakenly given a third dose of Heplisav one month after 2nd dose
Age: 3.0
Sex: M
Vaccine: TDAP
Symptoms: Product administered to patient of inappropriate age, Wrong product administered
Clinical narrative: Tdap given to 3 year old instead of DTaP
Age: 65.0
Sex: F
Vaccine: VARZOS
Symptoms: Chills, Fatigue, Pain, Pyrexia
Clinical narrative: Symptoms onset the next day in the morning included low-grade fever (99.7), aches, chills,  tiredness.
Age: 53.0
Sex: F
Vaccine: VARZOS
Symptoms: Impetigo
Clinical narrative: Pt indicated on 2/5/24 that she had an Impetigo outbreak on the third day after her 2nd Shingrix immunization. She indicated that she had cold sores about 3 days post her 1st immunization of Shingrix prior to receiving  her first shot. She corrected herself that the after first immunization that it was impetigo, not cold sores, as well when she called 2/5/24. I asked if the Impetigo was diagnosed, and she replied no but she knew it was Impetigo.
Age: 7.0
Sex: M
Vaccine: FLU4
Symptoms: Injection site rash, Rash, Tongue eruption
Clinical narrative: Patient's parents stated noticed a small rash to patient's left face near his mouth on Saturday morning around 0900. The rash got bigger throughout Saturday affecting his upper left arm, left shoulder to the back, left neck and 3/4 of the patient's face and rash on the tongue, denies wheezing or difficulty breathing.  Parents took the patient to urgent care on Sunday around 12:30 PM.  Outcome-N/A
Age: 20.0
Sex: F
Vaccine: COVID19, FLU4, HEP, MMR, TDAP
Symptoms: Dizziness, Nausea
Clinical narrative: Patient vaccinated at 3:19PM, (Moderna, Fluarix, Hep B, MMR, and Tdap) At 3:25PM Patient stated feeling nauseated and dizzy. At 3:27PM vital signs are as follow: B/p 86/54, pulse 76,)2 99%, Res 18, Patient stated she ate lunch an hour before vaccination. At 3:33PM Provider was called. At 3:35PM vital signs are as follows : B/P 88/71, Pulse 70, 02 100%, provider advise continue monitoring the patient. Patient stated feeling better. and symptoms had resolved. At 3:48PM vital signs are as follows: 116/68, pulse 69, O2 99% respiration rate 18, temp 97.7F.  ambulance was not called. Provider cleared patient at 4:00pm
Age: 14.0
Sex: F
Vaccine: TDAP
Symptoms: Cough, Oropharyngeal pain, Rash, Rash erythematous, Rash pruritic
Clinical narrative: Patient's family reports the patient has begun having a cough and sore throat accompanied with a itching pink rash on her stomach and legs on 2/5/24.
Age: 19.0
Sex: U
Vaccine: MMRV
Symptoms: Vaccination failure
Clinical narrative: No additional AE, no PQC; HCP called to report a 19 year old patient had low titers for MMR and VARICELLA and was given PROQUAD on 23JAN2024. No additional AE/no PQC.; This spontaneous report was received from a register nurse, concerning a 19-year-old patient of unknown age and gender.   The patient's medical history, concurrent conditions and concomitant medication were not reported.  It was reported that the patient had low titers for measles, mumps and rubella (MMR) and VARICELLA. Consequently on 23-JAN-2024, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) injection, 0.5 milliliter, once, l(ot #X020572 has been verified to be valid, expiration date reported as 03-FEB-2025, albumin status recombinant human albumin (rHa), administered for prophylaxis (strength, and route of administration were not provided). No AE reported.
Sex: U
Vaccine: PNC13, PPV
Symptoms: Abscess limb, Extradural abscess, Paraspinal abscess, Psoas abscess, Streptococcal abscess
Clinical narrative: S. pneumoniae thigh abscess; epidural abscess; paraspinal / psoas abscess; paraspinal / psoas abscess; S. pneumoniae thigh, calf deep abscess, epidural abscess, paraspinal / psoas; This spontaneous report was received from a physician refers to a 70-year-old patient of unknown gender. Historical drug included epidural steroid injection. No information on patient's medical history, current conditions and concomitant medications.  In 2019, the patient was vaccinated with pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) for prophylaxis (exact dose, dose number, route and site of administration, lot number and expiration date were not provided). Other suspect therapies included pneumococcal vaccine conj 13v (crm197) (PREVNAR 13).  On an unknown date the patient experienced abscess limb, streptococcal abscess, paraspinal abscess, psoas abscess and extradural abscess. The outcome of abscess limb, streptococcal abscess, paraspinal abscess, psoas abscess and extradural abscess was unknown. Action taken with pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) regarding the events was not applicable.  The causality between pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) and the events was not provided.  Upon internal review events extradural abscess, psoas abscess and paraspinal abscess were considered medically significant.
Sex: U
Vaccine: PNC, PPV
Symptoms: Pneumonia pneumococcal, Septic arthritis streptococcal
Clinical narrative: S. pneumoniae native shoulder septic arthritis; pneumonia.; This spontaneous report was received from a physician and refers to a 83-year-old patient of unknown gender. Historical condition included parainfluenzae virus infection. No information on patient's current conditions and concomitant medications was provided.  In 2005 the patient was vaccinated with pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) for prophylaxis (exact dose, dose number, route and site of administration, lot number and expiration date were not provided).  Other suspect therapies included pneumococcal vaccine conj 7v (crm197) (PREVNAR).  On an unknown date the patient experienced septic arthritis streptococcal and pneumonia pneumococcal. The outcome of septic arthritis streptococcal and pneumonia pneumococcal was unknown. Action taken pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) with regarding the events was not applicable.  The causality between pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) and the events was not provided.  Upon internal review events septic arthritis streptococcal and pneumonia pneumococcal were considered medically significant.
Sex: U
Vaccine: HEP
Symptoms: No adverse event, Product storage error
Clinical narrative: No additional AE reported; HCP called to report T/E case that occurred on 12/7/2023. HCP stated RECOMBIVAX HB was administered on 1/10/2024 to 1 patient; This spontaneous report has been received from a medical assistant, concerning a 6-day-old patient of unknown gender.  The patient's medical history, concurrent conditions, historical drugs, and concomitant therapies were not reported.  On 10-JUN-2024, the patient was vaccinated with the 1st dose of hepatitis b vaccine (recombinant) (RECOMBIVAX HB) intramuscular injection (lot number W023682 was verified to be valid, expiration date reported and confirmed as 21-MAY-2025) administered as prophylaxis (exact dose, route of administration, and anatomical location were not provided). The vaccine administered suffered a temperature excursion (TE) of 0.0 Celsius degrees on 07-DEC-2023, during a time frame of 1h 29min (Product storage error), and had not had previous temperature excursions. The TE case was supported based on in house stability data.  No other information nor additional additional adverse event (AE) were reported.
Age: 18.0
Sex: F
Vaccine: HPV9
Symptoms: Syncope, Tonic clonic movements
Clinical narrative: Tonic-clonic "motions"; fainted after third dose; This spontaneous report was received from employee and refers to a 18-year-old female patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported.  On 10-OCT-2023, the patient was vaccinated with third dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection (0.5 milliliter, lot #, expiration date, route of administration and anatomical location were not provided) for prevention of diseases caused by Human papillomavirus (HPV).  On 10-OCT-2023, the patient experienced tonic-clonic motions and fainted after third dose. On 10-OCT-2023, the patient recovered from the events. The action taken with suspect vaccine regarding the events was not applicable.  The causal relationship between the events and hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) was not provided.  Upon internal review, the events of tonic clonic movements and syncope were considered to be medically significant.
Age: 15.0
Sex: U
Vaccine: HPV9
Symptoms: Inappropriate schedule of product administration, No adverse event
Clinical narrative: No additional AE; First dose administered on 10-FEB-2023, second dose on 01-FEB-2024; This spontaneous report was received from a pharmacist and refers to a 16-year-old patient of unknown gender. The patient's pertinent medical history, drug reactions or allergies and concomitant therapies were not reported.  On 10-FEB-2023, the patient was vaccinated with the first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection and on 01-FEB-2024, the patient was vaccinated with the second dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection (Inappropriate schedule of product administration); both administered for prophylaxis (strength, lot #, expiry date, anatomical location and route of administration were not provided for either dose). No additional adverse events reported.
Age: 64.0
Sex: M
Vaccine: RSV
Symptoms: Injection site scab, Injection site swelling, Injection site ulcer
Clinical narrative: swelling at the injection sight; Ulceration at injection site; scabbing at the injection site; This non-serious case was reported by a physician via sales rep and described the occurrence of injection site swelling in a 64-year-old male patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   On 27-DEC-2023, the patient received Arexvy (left arm). On an unknown date, an unknown time after receiving Arexvy, the patient experienced injection site swelling (Verbatim: swelling at the injection sight), injection site ulcer (Verbatim: Ulceration at injection site) and injection site scab (Verbatim: scabbing at the injection site). The outcome of the injection site swelling, injection site ulcer and injection site scab were not reported.   It was unknown if the reporter considered the injection site swelling, injection site ulcer and injection site scab to be related to Arexvy.     It was unknown if the company considered the injection site swelling, injection site ulcer and injection site scab to be related to Arexvy.   Additional Information: GSK report date: 26-JAN-2024 The reporter reported that the Arexvy vaccine was administered in office into left arm, no other vaccines administered during that office encounter. The office did not know the lot or expiry date. The patient reported swelling, ulceration and scabbing at the injection site. The reporter consent to follow up via email to Medical Assistant.
Sex: U
Vaccine: RSV
Symptoms: Influenza
Clinical narrative: Flu; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of influenza in a patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   On an unknown date, the patient received Arexvy. On an unknown date, less than a day after receiving Arexvy, the patient experienced influenza (Verbatim: Flu). The outcome of the influenza was not resolved.   It was unknown if the reporter considered the influenza to be related to Arexvy.     It was unknown if the company considered the influenza to be related to Arexvy.   Additional Information: GSK Receipt Date: 29-JAN-2024 The case was received from the consumer via (Open field AE monitoring) interactive digital media. The patient was received Arexvy vaccine and developed flu condition the same night after the shot and had been this way for days now.  The patient was looking at the side effects. The follow-up could not be possible as no contact details were available.
Age: 72.0
Sex: F
Vaccine: VARZOS
Symptoms: Gait disturbance, Magnetic resonance imaging neck, Neck pain, Pyrexia, Vaccine positive rechallenge
Clinical narrative: Severe Neck Pain; patient had a fever; difficult to walk; This non-serious case was reported by a nurse via call center representative and described the occurrence of neck pain in a 72-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included clavicle fracture (Broken Clavicle on Left side 2016), rotator cuff tear (Left Rotator Cuff tear and surgical repair: 2006) and rotator cuff repair (and surgical repair: 2006). Previously administered products included Shingrix with an associated reaction of neck pain (patient received 1st dose on 2nd November 2023 and experienced neck pain, reference case US2024013740), Meloxicam and Prednisone. Concurrent medical conditions included arthritis of neck.   On 08-JAN-2024, the patient received the 2nd dose of Shingrix (left deltoid). On 08-JAN-2024, less than a day after receiving Shingrix, the patient experienced neck pain (Verbatim: Severe Neck Pain). In JAN-2024, the patient experienced fever (Verbatim: patient had a fever) and walking difficulty (Verbatim: difficult to walk). Rechallenge with Shingrix was positive. The outcome of the neck pain and walking difficulty were not resolved and the outcome of the fever was unknown.   It was unknown if the reporter considered the neck pain, fever and walking difficulty to be related to Shingrix.     It was unknown if the company considered the neck pain, fever and walking difficulty to be related to Shingrix.   Linked case(s) involving the same patient:  US2024013740   Additional Information: GSK receipt date: 30-JAN-2024 The reporter was the patient who was also a nurse. The patient received the first dose of Shingrix and experienced neck pain all over her neck.  The patient received the second dose of Shingrix and experienced severe pain in her neck later that night.   The patient had a fever also.   The pain was described as an 8-9 on a scale of 10.   The next morning, the patient went to an orthopedic walk in clinic and subsequently had an MRI that showed arthritis in her neck, but not enough to cause the pain that the patient was having.   The patient used a heating pad, a TENS unit, ointments, and Physical Therapy exercises to alleviated the pain.  The patient was scheduled to have steroid injections to treat the pain. Prior to receiving Shingrix the patient was very active, walking 25-30 miles per week, and kayaking.   Now, (at the time of reporting) the patient found it difficult to walk, and currently described the pain as 5-6 on a scale of 10. The reporter consented to follow up.; Sender's Comments:  US-GSK-US2024013740:same patient different dose
Sex: F
Vaccine: VARZOS
Symptoms: Chills, Headache
Clinical narrative: shivering after receiving Shingrix; headache after receiving Shingrix; This non-serious case was reported by a consumer via call center representative and described the occurrence of shivering in a 61-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced shivering (Verbatim: shivering after receiving Shingrix) and headache (Verbatim: headache after receiving Shingrix). The outcome of the shivering and headache were unknown.   It was unknown if the reporter considered the shivering and headache to be related to Shingrix.     It was unknown if the company considered the shivering and headache to be related to Shingrix.   Additional Information: GSK receipt date: 29-JAN-2024 The patient self reported this case. The reporter reported that the he/she experienced headache and shivering after receiving SHINGRIX. The reporter did not consented to follow up.
Age: 64.0
Sex: M
Vaccine: RSV
Symptoms: Product preparation issue
Clinical narrative: Administered only adjuvant component of Arexy in error; Inappropriate reconstitution technique; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of inappropriate dose of vaccine administered in a 64-year-old male patient who received RSVPreF3 adjuvanted (Arexvy) (batch number 45mg3, expiry date 10-JUL-2025) for prophylaxis.   On 11-JAN-2024, the patient received Arexvy. On 11-JAN-2024, an unknown time after receiving Arexvy, the patient experienced inappropriate dose of vaccine administered (Verbatim: Administered only adjuvant component of Arexy in error) and inappropriate preparation of medication (Verbatim: Inappropriate reconstitution technique). The outcome of the inappropriate dose of vaccine administered and inappropriate preparation of medication were unknown.   Additional Information: GSK Receipt Date: 29-JAN-2024. The reporter stated that the patient was administered only adjuvant component of Arexy in error which led to inappropriate dose of vaccine administered and inappropriate preparation of medication. The reporter consented to follow up. This is 1 of 5 cases reported by same reporter.; Sender's Comments:  US-GSK-US2024013410:Same reporter US-GSK-US2024013415:Same reporter US-GSK-US2024013414:Same reporter US-GSK-US2024013413:Same reporter
Age: 1.0
Sex: F
Vaccine: DTAPIPV
Symptoms: Product administered to patient of inappropriate age, Wrong product administered
Clinical narrative: Administration of Kinrix to a 12 month old child instead of Havrix; Administration of Kinrix to a 12 month old child instead of Havrix; This non-serious case was reported by a other health professional via call center representative and described the occurrence of wrong vaccine administered in a 12-month-old female patient who received DTPa-IPV (Kinrix) (batch number 34MF9, expiry date 13-FEB-2026) for prophylaxis.   On 29-JAN-2024, the patient received Kinrix. On 29-JAN-2024, an unknown time after receiving Kinrix, the patient experienced wrong vaccine administered (Verbatim: Administration of Kinrix to a 12 month old child instead of Havrix) and inappropriate age at vaccine administration (Verbatim: Administration of Kinrix to a 12 month old child instead of Havrix). The outcome of the wrong vaccine administered and inappropriate age at vaccine administration were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 29-JAN-2024: The medical assistant reported that 12 month old child administered Kinrix instead of Havrix which led to wrong vaccine administered and inappropriate age at vaccine administration. The reporter consented to follow up.
Age: 2.0
Sex: M
Vaccine: DTAP
Symptoms: Product storage error
Clinical narrative: On October 9th 2023, the vaccine went down to min 26.6F for 2 hrs and 35 minutes.; This non-serious case was reported by a other health professional via call center representative and described the occurrence of incorrect storage of drug in a male patient who received DTPa (Infanrix) (batch number 9hp9z, expiry date 21-APR-2024) for prophylaxis.   On 20-DEC-2023, the patient received Infanrix. On an unknown date, an unknown time after receiving Infanrix, the patient experienced incorrect storage of drug (Verbatim: On October 9th 2023, the vaccine went down to min 26.6F for 2 hrs and 35 minutes.). The outcome of the incorrect storage of drug was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 26-JAN-2024 The reporter was a medical assistant. The reporter reported that a patient was administered frozen Infanrix and on 9th October 2023, the vaccine went down to min 26.6 degree F for 2 hours and 35 minutes, which led to incorrect storage of vaccine. The reporter consented to follow up. This was 1 of 6 cases reported by the same reporter.; Sender's Comments:  US-GSK-US2024013465:Same reporter US-GSK-US2024013460:Same reporter US-GSK-US2024013461:Same reporter US-GSK-US2024013458:Same reporter US-GSK-US2024013455:Same reporter
Age: 4.0
Sex: F
Vaccine: DTAPIPV
Symptoms: Product storage error
Clinical narrative: was administered frozen Kinrix, the vaccine went down to min 26.6F for 2 hrs and 35 minutes.; This non-serious case was reported by a other health professional via call center representative and described the occurrence of incorrect storage of drug in a 4-year-old female patient who received DTPa-IPV (Kinrix) (batch number 3ks4f, expiry date 22-MAR-2024) for prophylaxis.   On 16-NOV-2023, the patient received Kinrix. On an unknown date, an unknown time after receiving Kinrix, the patient experienced incorrect storage of drug (Verbatim: was administered frozen Kinrix, the vaccine went down to min 26.6F for 2 hrs and 35 minutes.). The outcome of the incorrect storage of drug was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 29-JAN-2024 A medical assistant reported that a patient was administered frozen Kinrix, on October 9th 2023, the vaccine went down to min 26.6F for 2 hrs and 35 minutes which led to incorrect storage of drug. The reporter Consented to follow up. This is 1 of 6 cases reported by same reporter.; Sender's Comments:  US-GSK-US2024013461:Same reporter US-GSK-US2024013460:Same reporter US-GSK-US2024013459:Same reporter US-GSK-US2024013458:Same reporter US-GSK-US2024013455:Same reporter
Age: 1.0
Sex: M
Vaccine: HEP
Symptoms: Product storage error
Clinical narrative: administration of Engerix-B that was delivered after 5 days shipping, was "out of storage range" when received; This non-serious case was reported by a nurse via call center representative and described the occurrence of incorrect storage of drug in a 1-year-old male patient who received HBV (Engerix B pediatric) (batch number H39Z4, expiry date 04-DEC-2025) for prophylaxis.   On 29-JAN-2024, the patient received Engerix B pediatric. On an unknown date, an unknown time after receiving Engerix B pediatric, the patient experienced incorrect storage of drug (Verbatim: administration of Engerix-B that was delivered after 5 days shipping, was "out of storage range" when received). The outcome of the incorrect storage of drug was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 29-JAN-2024 The reporter requested the stability data and Centers for Disease Control and Prevention recommendations after the administration of engerix-b that was delivered 5 days shipping was out of storage range when received. The specific time and temperature for storage condition was unknown. The reporter stated that distributor will replace and refund vaccines. Vaccines were delivered on the day of reporting and administered to 2 patients on the day of reporting, which led to incorrect storage of drug. This case has been linked to the US2024013464 case reported by the same reporter. The reporter consented to follow-up.; Sender's Comments:  US-GSK-US2024013464:Same reporter/ Different patient
Sex: U
Vaccine: TDAP
Symptoms: Expired product administered
Clinical narrative: a Medical Assistant inadvertently administered an expired Boostrix(exp:12/9/23) dose to a patient today on 1/29/24.; This non-serious case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a patient who received DTPa (Reduced antigen) (Boostrix) (batch number 7ZD7L, expiry date 09-DEC-2023) for prophylaxis.   On 29-JAN-2024, the patient received Boostrix. On 29-JAN-2024, an unknown time after receiving Boostrix, the patient experienced expired vaccine used (Verbatim: a Medical Assistant inadvertently administered an expired Boostrix(exp:12/9/23) dose to a patient today on 1/29/24.). The outcome of the expired vaccine used was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 29-JAN-2024 Practice Manager reported a Medical Assistant inadvertently administered an expired Boostrix dose to a patient, which led to expired vaccine used. The reporter inquired was there any grace period. The reporter did not consent to follow-up.
Age: 1.08
Sex: F
Vaccine: HEPA
Symptoms: Incorrect dose administered
Clinical narrative: the use of an adult dose of Havrix in pediatric patients; Overdose; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult product administered to child in a 13-month-old female patient who received HAV (Havrix 1440 adult) for prophylaxis.   On 29-JAN-2024, the patient received the 1st dose of Havrix 1440 adult. On 29-JAN-2024, an unknown time after receiving Havrix 1440 adult, the patient experienced adult product administered to child (Verbatim: the use of an adult dose of Havrix in pediatric patients) and overdose (Verbatim: Overdose). The outcome of the adult product administered to child and overdose were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 29-JAN-2024 A Nurse contacted to inquire about Havrix and what information was available about any information about the use of an adult dose of Havrix in pediatric patients. Partial information given. The reporter reported that the 13 month old patient received adult dose of Havrix vaccine, which led to overdose and adult product administered to child. The Vaccine Administration Facility was the same as Primary Reporter. The reporter did not consent to follow-up.
Age: 51.0
Sex: F
Vaccine: HEPAB
Symptoms: Extra dose administered, No adverse event
Clinical narrative: a female patient received a 4th dose of Twinrix yesterday by mistake; This non-serious case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 51-year-old female patient who received HAB (Twinrix adult) for prophylaxis.   On 30-JAN-2024, the patient received the 4th dose of Twinrix adult. On 30-JAN-2024, an unknown time after receiving Twinrix adult, the patient experienced extra dose administered (Verbatim: a female patient received a 4th dose of Twinrix yesterday by mistake). The outcome of the extra dose administered was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 30-JAN-2024 The reporter was a registered nurse who stated a patient received a 4th dose of Twinrix the day before reporting by mistake, which led to extra dose administered. According to reporter, patient was doing fine. The reporter consented to follow up.
Age: 72.0
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Neck pain
Clinical narrative: Neck pain all over her neck; This non-serious case was reported by a nurse via call center representative and described the occurrence of neck pain in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included clavicle fracture (broken clavicle on left side in 2016) and rotator cuff tear (left Rotator Cuff tear and surgical repair in 2006). Concurrent medical conditions included arthritis of neck.   On 02-NOV-2023, the patient received the 1st dose of Shingrix (left deltoid). On an unknown date, less than 3 months after receiving Shingrix, the patient experienced neck pain (Verbatim: Neck pain all over her neck). The patient was treated with prednisone. The outcome of the neck pain was not reported.   It was unknown if the reporter considered the neck pain to be related to Shingrix.     It was unknown if the company considered the neck pain to be related to Shingrix.   Linked case(s) involving the same patient:  US2024AMR015766   Additional Information: GSK Receipt Date: 30-Jan-2024 The patient was self-reported this case. The patient received the first dose of Shingrix vaccine experienced neck pain all over her neck.  The patient took Meloxicam and Prednisone but did not relieve the pain.   The pain in her neck became worse and she was prescribed physical therapy and muscle relaxants. The reporter consented to follow up. This US2024AMR015766 case has been linked to the case reported by the same reporter for same patient.; Sender's Comments:  US-GSK-US2024AMR015766:same patient different dose